ONCOLOGY Vol 23 No 1 | Oncology

Expanding Role of Ovarian Suppression/ Ablation in Premenopausal ER-Positive Breast Cancer: Issues and Opportunities

January 02, 2009

Luteinizing hormone-releasing hormone analogs (LHRHa) are often used alone or in combination with tamoxifen to suppress ovarian function in premenopausal women with endocrine-responsive breast cancer. However, aromatase inhitiors (AIs) are now the preferred first-line endocrine treatment for postmenopausal women with breast cancer.

Ovarian Suppression/Ablation in Premenopausal ER-Positive Breast Cancer Patients

January 01, 2009

Developed over a century ago,[1] endocrine therapy remains the most effective and the most clearly targeted form of systemic therapy for breast cancer. Endocrine treatments work best in women whose tumors are positive for estrogen receptors (ER) and/or progesterone receptors (PR).

Aggressive Surgical Therapy for Metastatic Disease Is Appropriate in the Current Management of Melanoma

January 01, 2009

Small bowel metastases from melanoma are uncommon. While the authors reference two studies that reported a large proportion of patients with small bowel metastases, the true incidence of gastrointestinal (GI) lesions in melanoma patients is much lower.

A Patient With Metastatic Melanoma of the Small Bowel

January 02, 2009

Melanoma frequently metastasizes to the small bowel. In this installment of Clinical Quandaries, we describe the case of 74-year-old man who presented with this rare but well described manifestation of malignant melanoma

Pharmacology of Anticancer Agents in the Elderly: The Pharmacist’s Perspective

January 02, 2009

In this issue of ONCOLOGY, Balducci[1] reviews principles for treating elderly patients with antineoplastic therapy. This paper begins by defining baseline terminology such as age and frailty, while providing an overview of applied techniques of discerning a patient’s functional impairment or disability.

Controversies in the Surgical Management of GIST in the Era of Imatinib

January 02, 2009

In the pre-imatinib era, surgery was the only effective treatment for gastrointestinal stromal tumor (GIST). However, this treatment modality was often either not possible or insufficient for cure due to the aggressive nature of this disease.

Perioperative Treatment of Gastrointestinal Stromal Tumors

January 02, 2009

Gastrointestinal stromal tumors (GISTs) originate from the interstitial cells of Cajal or a precursor and are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract.[1] Although GISTs often present as localized masses, they are typified by a high risk of metastatic relapse, most commonly in the liver and peritoneum.

Optimizing Endocrine Therapy in Premenopausal ER-Positive Breast Cancer Patients

January 01, 2009

The optimal endocrine therapy for premenopausal women with hormone receptor–positive early breast cancer remains elusive. Dr. Pritchard presents a thoughtful review of this important topic, including the historic context for the current controversy regarding the utility of ovarian suppression (either by medication or permanent ablation) in the adjuvant treatment of young women with breast cancer.